"Cholesterol, LDL" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cholesterol which is contained in or bound to low density lipoproteins (LDL), including CHOLESTEROL ESTERS and free cholesterol.
| Descriptor ID |
D008078
|
| MeSH Number(s) |
D04.210.500.247.808.197.244 D10.532.515.500 D10.570.938.208.275 D12.776.521.550.500
|
| Concept/Terms |
Cholesterol, LDL- Cholesterol, LDL
- Low Density Lipoprotein Cholesterol
- beta-Lipoprotein Cholesterol
- Cholesterol, beta-Lipoprotein
- beta Lipoprotein Cholesterol
- LDL Cholesterol
|
Below are MeSH descriptors whose meaning is more general than "Cholesterol, LDL".
Below are MeSH descriptors whose meaning is more specific than "Cholesterol, LDL".
This graph shows the total number of publications written about "Cholesterol, LDL" by people in this website by year, and whether "Cholesterol, LDL" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1997 | 0 | 3 | 3 |
| 1999 | 1 | 1 | 2 |
| 2000 | 0 | 2 | 2 |
| 2001 | 1 | 0 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 2 | 0 | 2 |
| 2006 | 0 | 2 | 2 |
| 2007 | 0 | 2 | 2 |
| 2008 | 3 | 1 | 4 |
| 2009 | 0 | 2 | 2 |
| 2010 | 1 | 0 | 1 |
| 2011 | 1 | 1 | 2 |
| 2012 | 1 | 1 | 2 |
| 2013 | 4 | 4 | 8 |
| 2014 | 4 | 5 | 9 |
| 2015 | 4 | 2 | 6 |
| 2016 | 1 | 5 | 6 |
| 2017 | 4 | 4 | 8 |
| 2018 | 3 | 3 | 6 |
| 2019 | 4 | 2 | 6 |
| 2020 | 6 | 4 | 10 |
| 2021 | 0 | 4 | 4 |
| 2022 | 1 | 8 | 9 |
| 2023 | 0 | 10 | 10 |
| 2024 | 4 | 3 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cholesterol, LDL" by people in Profiles.
-
Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy. Eur Heart J. 2024 Jul 12; 45(27):2422-2434.
-
Inclisiran in individuals with diabetes or obesity: Post hoc pooled analyses of the ORION-9, ORION-10 and ORION-11 Phase 3 randomized trials. Diabetes Obes Metab. 2024 Aug; 26(8):3223-3237.
-
Cardiovascular outcomes in patients with homozygous familial hypercholesterolaemia on lipoprotein apheresis initiated during childhood: long-term follow-up of an international cohort from two registries. Lancet Child Adolesc Health. 2024 Jul; 8(7):491-499.
-
Heart groups in South Africa advocate for tighter LDL-C control and lipoprotein(a) testing to curb atherosclerotic cardiovascular disease. S Afr Med J. 2024 May 09; 114(5):e1973.
-
Sex Differences in Diagnosis, Treatment, and Cardiovascular Outcomes in Homozygous Familial Hypercholesterolemia. JAMA Cardiol. 2024 Apr 01; 9(4):313-322.
-
Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies. Arterioscler Thromb Vasc Biol. 2024 May; 44(5):1156-1164.
-
Estimating potential cardiovascular health benefits of improved population level control of LDL cholesterol through a twice-yearly siRNA-based approach: A simulation study of a health-system level intervention. Atherosclerosis. 2024 Apr; 391:117472.
-
Safety and Tolerability of Inclisiran for?Treatment of Hypercholesterolemia in?7 Clinical Trials. J Am Coll Cardiol. 2023 12 12; 82(24):2251-2261.
-
Coronary microcirculatory dysfunction in hypercholesterolemic patients with COVID-19: potential benefit from cholesterol-lowering treatment. Ann Med. 2023 12; 55(1):2199218.
-
Modelling the potential long-term survival benefit of evinacumab treatment vs. standard of care in patients with homozygous familial hypercholesterolaemia. Eur J Prev Cardiol. 2023 11 30; 30(17):1874-1880.